Donna Hackett

Donna has more than 25 years’ experience with a successful track record of wealth creation in commercialising life science technologies through deals including partnering of products and technologies and venture financing.

Previous roles include being on the executive team of Abzena plc as SVP IP Commercial and Legal Affairs, where she was responsible for the legal IP and transactional activity, and COO and executive board member of Stabilitech.

At UCL, she led BioPharm Technology Transfer and was instrumental in starting BioVex with the academic founders, securing the first three rounds of funding. BioVex was sold to Amgen for $1 billion and the product is on the market.